Articles and Blogs

The Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion (“OPDP”) started 2025 with two Untitled Letters, one in February and one in March, potentially signaling more enforcement for the year. OPDP issued only five enforcement letters in 2023 and 2024, with a heavy focus on influencer marketing. However, on April 1, 2025,... READ MORE

It is hard to believe that spring is finally here and the Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion (“OPDP”) has yet to take any enforcement action in 2023. While this seems unusual, it appears consistent with the OPDP’s seemingly measured approach to enforcement actions in recent years. It may also... READ MORE